Bioactive compounds against SARS-CoV-2 / edited by Jen-Tsung Chen
"Coronaviruses can cause illness, severe disease, and death; e.g. Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and COVID-19. Vaccine development and antiviral drugs are challenged by the propensity for viral mutations allowing these viruses to evade such therapies"--.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Boca Raton: CRC Press ; 2023 |
| Ausgabe: |
First edition |
| Weitere Ausgaben: |
Erscheint auch als Druck-Ausgabe: Bioactive compounds against SARS-CoV-2 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jen-Tsung [HerausgeberIn] |
|---|
| Links: |
doi.org [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| Nlm: |
QW 168.5.C8 |
|---|---|
| Themen: |
Antiviral Agents |
| RVK: |
|---|
| Anmerkungen: |
Includes bibliographical references and index |
|---|
| Umfang: |
1 Online-Ressource (pages cm) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1870353307 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1870353307 | ||
| 003 | DE-627 | ||
| 005 | 20231219145255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231115s2023 xxu|||||o 00| ||eng c | ||
| 020 | |a 9781003323884 |c ebook |9 978-1-003-32388-4 | ||
| 020 | |a 9781000909098 |9 978-1-000-90909-8 | ||
| 020 | |a 9781000909081 |9 978-1-000-90908-1 | ||
| 035 | |a (DE-627)1870353307 | ||
| 035 | |a (DE-599)KXP1870353307 | ||
| 035 | |a (OCoLC)1409398426 | ||
| 040 | |a DE-627 |b eng |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XD-US | ||
| 050 | 0 | |a RA644.C67 | |
| 060 | 0 | |a QW 168.5.C8 | |
| 082 | 0 | |a 614.5/924144 |2 23/eng/20230621 | |
| 084 | |a WF 3500 |q SEPA |2 rvk |0 (DE-625)rvk/148346: | ||
| 245 | 1 | 0 | |a Bioactive compounds against SARS-CoV-2 |c edited by Jen-Tsung Chen |
| 250 | |a First edition | ||
| 264 | 1 | |a Boca Raton |b CRC Press |c 2023 | |
| 300 | |a 1 Online-Ressource (pages cm) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 520 | |a "Coronaviruses can cause illness, severe disease, and death; e.g. Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and COVID-19. Vaccine development and antiviral drugs are challenged by the propensity for viral mutations allowing these viruses to evade such therapies"-- | ||
| 650 | 2 | |a SARS-CoV-2 |x drug effects | |
| 650 | 2 | |a COVID-19 Vaccines | |
| 650 | 2 | |a Antiviral Agents | |
| 650 | 2 | |a Drug Resistance, Viral | |
| 650 | 2 | |a Mutation |x drug effects | |
| 650 | 2 | |a COVID-19 Drug Treatment | |
| 700 | 1 | |a Chen, Jen-Tsung |e herausgeberin |4 edt | |
| 776 | 1 | |z 9781032347998 | |
| 776 | 1 | |z 9781032347967 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Bioactive compounds against SARS-CoV-2 |b First edition |d Boca Raton : CRC Press, 2024 |h 275 Seiten |w (DE-627)1851987614 |z 9781032347998 |z 9781032347967 |
| 856 | 4 | 0 | |u https://doi.org/10.1201/9781003323884 |x Verlag |z lizenzpflichtig |
| 912 | |a ZDB-7-TFC | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 936 | r | v | |a WF 3500 |b Tier- und menschenpathogene Viren |k Biologie |k Mikrobiologie |k Virologie |k Einteilung der Viren nach wirtsspezifischer Pathogenität |k Tier- und menschenpathogene Viren |0 (DE-627)1271584883 |0 (DE-625)rvk/148346: |0 (DE-576)201584883 |
| 951 | |a BO | ||
| 953 | |2 045F |a 614.5/924144 | ||
| 980 | |2 20 |1 01 |x 0084 |b 4407735198 |h CATDESC_TF-EB |u CATDESC_TF-EB |y z |z 08-12-23 | ||
| 981 | |2 20 |1 01 |x 0084 |r https://doi.org/10.1201/9781003323884 | ||
| 995 | |2 20 |1 01 |x 0084 |a CATDESC_TF-EB | ||
| 995 | |2 20 |1 01 |x 0084 |a ACQ | ||